#Japan #Tokyo #SBI Group #NANO MRNA #Biohealthcare

NANO MRNA and SBI Group: A Revolutionary Partnership in Healthcare Financing

On October 8, 2025, NANO MRNA Co., Ltd. hosted a press conference at the Kabuto Club in the Tokyo Stock Exchange to announce their collaboration with SBI Securities and SBI Shinsei Corporate Investment, marking a significant shift in the healthcare and biotechnology sectors.

NANO MRNA, a biotech venture recognized for its RNA drug development, is venturing into the finance sector. This approach deviates from the traditional pharmaceutical press conferences, suggesting a groundbreaking, cross-industry collaboration that stirred excitement among attendees.

During the conference, key figures including SBI Shinsei Corporate Investment's CEO Kenji Uesaka, SBI Securities' Senior Managing Director Kyomichi Ishii, NANO MRNA’s President Shiro Akinaga, future Nano Bridge Investment CEO Tomo Iino, and Chief Growth Officer Nobuhiro Tomidokoro shared insights on the new partnership’s background and future vision.

Financial Solutions for Healthcare Potentials

Shiro Akinaga opened the conference by highlighting the financial challenges faced by Japanese biotech ventures. He stated,

“While our company has developed robust drug discovery technology, the primary challenges for Japanese biotech startups are funding acquisition and sustaining growth. By integrating financial functions, we aim to establish a conglomerate model in healthcare. This will support innovative companies and enhance shareholder value simultaneously.”

In response to these challenges, NANO MRNA announced the establishment of a new investment firm, Nano Bridge Investment, which will collaborate with SBI Shinsei Corporate Investment to manage a fund integrating stock-based M&A and capital financing with a vision to accelerate the growth of promising biotech and healthcare enterprises.

SBI Group's Alignment with Industry Challenges

SBI Securities’ Kyomichi Ishii addressed the critical investment issues facing Japan's biotech and healthcare industries, specifically noting a 'biotech 100 billion problem' in which investor risk appetite has recently declined, limiting the initial market capitalization of biotech companies to around 10 billion yen regardless of their development stage. This results in a negative cycle where companies must license out early or go public at lower valuations, missing their potential for exponential growth.

Ishii emphasized that overcoming these hurdles requires strategic M&A and collaboration among multiple startups, which aligns perfectly with NANO MRNA's new conglomerate model. He described it as a practical solution to the funding crisis.

Vision Towards the Future

Kenji Uesaka from SBI Shinsei Corporate Investment expressed tremendous optimism about their collaborative fund, stating,

“Many biotech ventures possess promising pipelines but struggle with funding, leading to a bottleneck in growth. Our joint fund aims to provide liquidity to existing shareholders while offering new investors an opportunity to enter at a fair value.”

Uesaka believes this model won't merely be a secondary investment but will herald a movement that could trigger a seismic shift in Japan's biotech ecosystem, enhancing structural financial flows within the industry.

Growth Strategy Led by the New Executive Team

At the heart of this new initiative is Tomo Iino, the newly appointed CIO, along with CGO Nobuhiro Tomidokoro, who brings a wealth of experience from Takeda Pharmaceutical. Iino explained,

“Our model is unprecedented in Japan's biotech and healthcare sectors. We aim to acquire majority stakes in target companies through stock issuance while funding their growth via our partnership fund,” highlighting the integration of M&A with growth-stage investments.

Furthermore, Tomidokoro emphasized the potential of unearthing buried technologies within many companies and combining them with healthcare applications for accelerated growth.

Engaging Dialogue and Future Aspirations

Following the presentations, a lively Q&A session emerged, addressing governance systems and investment criteria. The speakers addressed each inquiry meticulously, demonstrating their preparedness to run this fund. Their commitment to transforming healthcare with financial backing reflected their vision for the future.

As they concluded, Akinaga reiterated,

“We aspire to accelerate innovation in healthcare through the power of finance and reshape the future of medicine.”

This announcement marks a historical moment for the healthcare conglomerate model, bridging financial solutions and healthcare innovation—a concept eagerly anticipated by the media and industry experts alike.

Learn More

A video of the press conference is available on YouTube, capturing the excitement and visionary intentions behind this new alliance.

Visit: Press Conference Video

Company Overview

Company Name: NANO MRNA Co., Ltd.
CEO: Shiro Akinaga
Headquarters: Atago Green Hills Mori Tower, 2-5-1 Atago, Minato-ku, Tokyo, Japan
Website: www.nanoｍrna.co.jp
Established: June 1996
Capital: ¥166 million
Employees: 20
Business Outline: Research and development, and manufacturing of pharmaceuticals.